title: Adriamycin-lipiodol suspension for i.a. chemotherapy of hepatocellular carcinoma.
abstract: Physicochemical properties of two types of adriamycin preparation, suspensions and emulsions prepared for i.a. chemotherapy of hepatocellular carcinoma, were investigated. A suspension was prepared by dispersing adriamycin directly into the lipid contrast medium, Lipiodol, whereas an emulsion was obtained by emulsifying an aqueous solution of adriamycin into Lipiodol. The dispersibility of the drug in each preparation was examined microscopically. The chemical stability of and drug release from the preparation were determined by high-performance liquid chromatography and spectrophotometry, respectively. The suspension was then given to ten patients with primary hepatocellular carcinoma. The suspension maintained good dispersibility without coagulation of drug particles, whereas coalescence of aqueous droplets and the resultant phase separation occurred 4 h after preparation of the emulsion. Both preparations maintained the initial drug content for at least 1 week at room temperature. The release of adriamycin was more prolonged in the suspension than in the emulsion. After i.a. administration of the suspension, a selective accumulation of Lipiodol in the tumor and decrease in serum alpha-fetoprotein (AFP) levels were found in most patients. A significant amount of adriamycin was still detected in hepatic specimens resected from two patients 1 and 2 months after treatment. These findings suggest that the adriamycin-Lipiodol suspension may be a useful preparation for targeting chemotherapy to hepatocellular carcinoma.
authors.affiliation: Department of Pharmacy, Shimane Medical University Hospital, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Katagiri
authors.forename: K
authors.initials: K
authors.lastname: Mabuchi
authors.forename: T
authors.initials: T
authors.lastname: Itakura
authors.forename: K
authors.initials: K
authors.lastname: Naora
authors.forename: K
authors.initials: K
authors.lastname: Iwamoto
authors.forename: Y
authors.initials: Y
authors.lastname: Nozu
authors.forename: S
authors.initials: S
authors.lastname: Hirai
authors.forename: N
authors.initials: N
authors.lastname: Ikeda
authors.forename: T
authors.initials: T
authors.lastname: Kawai
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D055598:Chemical Phenomena; D002627:Chemistry, Physical; D004317:Doxorubicin / Q000008:administration & dosage* / Q000494:pharmacology; D004341:Drug Evaluation; D004355:Drug Stability; D004655:Emulsions; D005260:Female; D006801:Humans; D007261:Infusions, Intra-Arterial; D007459:Iodized Oil / Q000008:administration & dosage* / Q000494:pharmacology; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D013535:Suspensions
chemical_list: D004655:Emulsions; D013535:Suspensions; D007459:Iodized Oil; D004317:Doxorubicin